{"entity":{"id":"cedars-sinai-cancer","kind":"institution","name":"Cedars-Sinai Cancer","aka":["Samuel Oschin Comprehensive Cancer Institute"],"tldr":"Los Angeles's largest non-profit hospital's cancer enterprise, known for bladder cancer biology, glioma immunotherapy and the Molecular Twin AI project.","summary":"Cedars-Sinai Cancer unites the Samuel Oschin Comprehensive Cancer Institute with Cedars-Sinai's regional network across Los Angeles. Director Dan Theodorescu's laboratory showed in 2023 that loss of the Y chromosome in bladder cancer drives immune evasion and sensitivity to checkpoint blockade; Keith Black's neurosurgery programme pioneered dendritic cell vaccines for glioma; and the Molecular Twin initiative combines multi-omics and AI to model individual patients, starting with pancreatic cancer. The centre has strong kidney, prostate, lung and women's cancer programmes and a phase 1 unit, and is pursuing NCI designation.","asOf":"2026-09-09","links":[{"label":"Cedars-Sinai Cancer","url":"https://www.cedars-sinai.org/programs/cancer.html"},{"label":"Clinical trials","url":"https://www.cedars-sinai.org/research/clinical-trials.html"}],"tags":[],"related":[],"cancers":["urothelial","glioblastoma","pancreatic","rcc"],"sections":["ai-computation"],"technologies":["digital-twins-trials","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["robert-figlin","armando-giuliano","mark-faries"],"bottlenecks":["b-data-silos"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Los Angeles, CA","country":"US","lat":34.075,"lng":-118.38,"institutionType":"hospital","website":"https://www.cedars-sinai.org/programs/cancer.html","programs":["Bladder cancer biology","Neuro-oncology immunotherapy","Molecular Twin (AI and multi-omics)"]},"route":"/institutions/cedars-sinai-cancer/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"}],"technology":[{"id":"digital-twins-trials","kind":"technology","name":"Digital twins and virtual control arms","route":"/technologies/digital-twins-trials/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"person":[{"id":"armando-giuliano","kind":"person","name":"Armando E. Giuliano","route":"/people/armando-giuliano/"},{"id":"mark-faries","kind":"person","name":"Mark B. Faries","route":"/people/mark-faries/"},{"id":"robert-figlin","kind":"person","name":"Robert Figlin","route":"/people/robert-figlin/"},{"id":"stephen-freedland","kind":"person","name":"Stephen J. Freedland","route":"/people/stephen-freedland/"}],"bottleneck":[{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/"}],"drug":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/"}],"trial":[{"id":"nct05318469","kind":"trial","name":"Ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer (Cedars-Sinai phase 1/2)","route":"/trials/nct05318469/"}]}}